Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9H251: Variant p.Arg301Gln

Cadherin-23
Gene: CDH23
Feedback?
Variant information Variant position: help 301 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Glutamine (Q) at position 301 (R301Q, p.Arg301Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In DFNB12. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 301 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 3354 The length of the canonical sequence.
Location on the sequence: help NSIFALDYISGVLTLNGLLD R ENPLYSHGFILTVKGTELND The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         NSIFALDYISGVLTLNGLLDRENPLYSHGFILTVKGTELND

Mouse                         NSIFALDYISGALTLNGLLDRENPLYSHGFILTVKGTELND

Rat                           NSIFALDYISGALTLNGLLDRENPLYSHGFILTVKGTELND

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 24 – 3354 Cadherin-23
Topological domain 24 – 3064 Extracellular
Domain 237 – 348 Cadherin 3
Alternative sequence 1 – 2240 Missing. In isoform 7 and isoform 9.
Alternative sequence 25 – 3127 Missing. In isoform 10 and isoform 11.



Literature citations
Distribution and frequencies of CDH23 mutations in Japanese patients with non-syndromic hearing loss.
Wagatsuma M.; Kitoh R.; Suzuki H.; Fukuoka H.; Takumi Y.; Usami S.;
Clin. Genet. 72:339-344(2007)
Cited for: VARIANTS DFNB12 LEU-240; GLN-301; PRO-1716 AND TRP-2029; VARIANTS TRP-1417; ILE-1711; MET-1807; ASN-1876; ILE-1908; CYS-2171; PRO-2227; ILE-2283; PRO-2473; HIS-2489; VAL-2669; VAL-2801 AND CYS-3175; Prevalence and clinical features of hearing loss patients with CDH23 mutations: a large cohort study.
Miyagawa M.; Nishio S.Y.; Usami S.;
PLoS ONE 7:E40366-E40366(2012)
Cited for: VARIANTS DFNB12 LEU-240; GLN-301; LYS-956; MET-1368; TRP-1417; ALA-1626; PRO-1716; TRP-2029; LYS-2287 AND LYS-2438; VARIANTS ASN-160; ILE-803; ILE-1415; GLY-1443; TRP-1588; ILE-1711; MET-1807; ASN-1876; ILE-1908; VAL-2130; CYS-2171; PRO-2227; PRO-2473; VAL-2669; VAL-2801; SER-2912 AND CYS-3175;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.